Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma

Clinical Immunology

Volumn 125, Issue 3, 2007, Pages 257-267

  Kim, Jung Han ^a   Lee, Yoon ^b   Bae, Yong Soo ^c   Kim, Won Seog ^a   Kim, Kihyun ^a   Im, Ho Yeong ^a   Kang, Won Ki ^a   Park, Keunchil ^a   Choi, Han Yong ^d   Lee, Hyun Moo ^d   Baek, So Young ^a   Lee, Hyunah ^a   Doh, Hyounmie ^e   Kim, Byong Moon ^e   Kim, Chae Young ^e   Jeon, ChoonJu ^b   Jung, Chul Won ^a  

^a Samsung Medical Center   (South Korea)

^b CreaGene Research Institute   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Dong A Pharmaceutical Company   (South Korea)

Author keywords

Dendritic cell; Immunotherapy; Renal cell carcinoma; Tumor lysate

Indexed keywords

CD40 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; TUMOR LYSATE PULSED DENDRITIC CELL VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER SURVIVAL; CELL CULTURE; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CULTURE MEDIUM; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INJECTION SITE PAIN; KIDNEY CARCINOMA; KIDNEY FAILURE; LYMPHOCYTE PROLIFERATION; MALE; METASTASIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; MYALGIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN INDURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS;

EID: 36148941016     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.07.014     Document Type: Article

References (35)

1. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., Ravaud A., Mercatello A., Peny J., Mousseau M., Philip P., and Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338 (1998) 1272-1278
2. Glaspy J.A. Therapeutic options in the management of renal cell carcinoma. Semin. Oncol. 29 (2002) 41-46
3. Goedegebuure P.S., Douville L.M., Li H., Richmond G.C., Schoof D.D., Scavone M., and Eberlein T.J. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. Clin. Oncol. 13 (1995) 1939-1949
4. Law T.M., Motzer R.J., Mazumdar M., Sell K.W., Walther P.J., O'Connell M., Khan A., Vlamis V., Vogelzang N.J., and Bajorin D.F. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76 (1995) 824-832
5. Höltl L., Rieser C., Papesh C., Ramoner R., Herhold M., Klocker H., Radmayr C., Stenzl A., Bartsch G., and Thurnher M. Cellular and hormonal immune responses in patients with metastatic renal cell cancer after vaccination with antigen-pulsed dendritic cells. J. Urol. 161 (1999) 777-782
6. Höltl L., Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., Rogatsch H., Barsoum A.L., Coggin Jr. J.H., and Thurnher M. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8 (2002) 3369-3376
7. Märten A., Flieger D., Renoth S., Weineck S., Albers P., Compes M., Schottker B., Ziske C., Engelhart S., Hanfland P., Krizek L., Faber C., von Ruecker A., Muller S., Sauerbruch T., and Schmidt-Wolf I.G. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol. Immunother. 51 (2002) 637-644
8. Gitlitz B.J., Belldegrun A.S., Zisman A., Chao D.H., Pantuck A.J., Hinkel A., Mulders P., Moldawer N., Tso C.L., and Figlin R.A. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. 26 (2003) 412-419
9. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., Coleman D., Niedzwiecki D., Gilboa E., and Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63 (2003) 2127-2133
10. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
11. Tazi A., Bouchonnet F., Grandsaigne M., Boumsell L., Hance A.J., and Soler P. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J. Clin. Invest. 91 (1993) 566-576
12. Austyn J.M. The dendritic cell system and anti-tumor immunity. In Vivo 7 (1993) 193-201
13. Thurnher M., Radmayr C., Ramoner R., Ebner S., Bock G., Klocker H., Romani N., and Bartsch G. Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer 68 (1996) 1-7
14. van den Eynde B.J., and van den Bruggen P. T cell defined tumor antigens. Curr. Opin. Immunol. 9 (1997) 684-693
15. Chaux P., Favre N., Martin M., and Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 72 (1997) 619-624
16. Troy A.J., Summers K.L., Davidson P.J., Atkinson C.H., and Hart D.N. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4 (1998) 585-593
17. Romani N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., Konwalinka G., Fritsch P.O., Steinman R.M., and Schuler G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180 (1994) 83-93
18. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., and Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27 (1997) 3135-3142
19. Baggers J., Ratzinger G., and Young J.W. Dendritic cells as immunologic adjuvants for the treatment of cancer. J. Clin. Oncol. 18 (2000) 3879-3882
20. Parmiani G., Pilla L., Castelli C., and Rivoltini L. Vaccination of patients with solid tumours. Ann. Oncol. 14 (2003) 817-824
21. Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T.B., Paragnik L., Kandemir A., Lee P.P., Schuler G., Knop J., and Enk A.H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93 (2001) 243-251
22. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., Croockewit S., Britten C.M., Torensma R., Adema G.J., Figdor C.G., and Punt C.J. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9 (2003) 5091-5100
23. McIlroy D., and Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol. Immunother. 52 (2003) 583-591
24. Fong L., Brockstedt D., Benike C., Wu L., and Engleman E.G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166 (2001) 4254-4259
25. Raychaudhuri S., and Rock K.L. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 16 (1998) 1025-1031
26. Wierecky J., Muller M.R., Wirths S., Halder-Oehler E., Dorfel D., Schmidt S.M., Hantschel M., Brugger W., Schroder S., Horger M.S., Kanz L., and Brossart P. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66 (2006) 5910-5918
27. Heiser A., Maurice M.A., Yancey D.R., Wu N.Z., Dahm P., Pruitt S.K., Boczkowski D., Nair S.K., Ballo M.S., Gilboa E., and Vieweg J. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166 (2001) 2953-2960
28. Steinman R.M., and Dodhapker M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94 (2001) 459-473
29. Barbuto J.A., Ensina L.F., Neves A.R., Bergami-Santos P., Leite K.R., Marques R., Costa F., Martins S.C., Camara-Lopes L.H., and Buzaid A.C. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. 53 (2004) 1111-1118
30. Shimizu K., Thomas E.K., Giedlin M., and Mule J.J. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 61 (2001) 2618-2624
31. Fong L., and Engleman E.G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18 (2000) 245-273
32. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15 (2003) 138-147
33. Yamamoto Y., Toi M., Kondo S., Matsumoto T., Syzuki H., Kitamura M., Tsuruta K., Taniguchi T., Okamoto A., Mori T., Yoshida M., Ikeda T., and Tominaga T. Concentration of vascular endothelial growth factor in the sere of normal controls and cancer patients. Clin. Cancer Res. 2 (1996) 821-826
34. Hegele A., Varga Z., von Knobloch R., Heidenreich A., Kropf J., and Hoffmann R. TGF-beta 1 in patients with renal cell carcinoma. Urol. Res. 30 (2002) 126-129
35. Bonfanti A., Lissoni P., Bucovec R., Rovelli F., Brivio F., and Fumagalli L. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer. Int. J. Biol. Markers 15 (2000) 161-164